Wheaton Acquires Bioreactor Flask Line from Wilson Wolf
|
By LabMedica International staff writers Posted on 25 Jul 2012 |
Wheaton Industries (Millville, NJ, USA) has acquired the CELLine bioreactor flask line for antibody and protein production from Wilson Wolf Manufacturing Corp. (New Brighton, MN, USA).
Wheaton has acquired the CELLine dual membrane, cell culture flasks from Wilson Wolf Manufacturing Corp. Wheaton has also entered into a long term strategic partnership with Wilson Wolf Manufacturing for additional product development in high density cell culture devices for the production of concentrated, cell secreted products.
CELLine flasks are easy to implement and are known worldwide for small-scale suspension and adherent cultures. The CELLine dual membrane bioreactor system is designed as a humane alternative to hybridoma culture in the peritoneal cavity of mice, also known as the ascites method.
The flasks enhance small-scale bioproduction for antibody and protein generation. Conventional in vivo or in vitro cell culture methods can be labor-intensive, result in low cell density, and require significant purification. The CELLine flasks address these three areas of limitation in a single use, repeatable technology. CELLine flasks are ready-to-use and disposable, and generate high cell density and high product concentration, while considerably reducing culture and processing time.
“We are excited to bring this innovative, high growth technology to Wheaton and to our customers around the world, enabling our customers’ life’s work. These products, combined with the existing Wheaton portfolio, support the advancement of antibody and protein research, development and production,” says Stephen R. Drozdow, president of Wheaton. “We are also proud to have an ongoing partner with Wilson Wolf, for collaboration and further advancement of cell culture products,” he added.
Related Links:
Wheaton Industries
Wilson Wolf Manufacturing
Wheaton has acquired the CELLine dual membrane, cell culture flasks from Wilson Wolf Manufacturing Corp. Wheaton has also entered into a long term strategic partnership with Wilson Wolf Manufacturing for additional product development in high density cell culture devices for the production of concentrated, cell secreted products.
CELLine flasks are easy to implement and are known worldwide for small-scale suspension and adherent cultures. The CELLine dual membrane bioreactor system is designed as a humane alternative to hybridoma culture in the peritoneal cavity of mice, also known as the ascites method.
The flasks enhance small-scale bioproduction for antibody and protein generation. Conventional in vivo or in vitro cell culture methods can be labor-intensive, result in low cell density, and require significant purification. The CELLine flasks address these three areas of limitation in a single use, repeatable technology. CELLine flasks are ready-to-use and disposable, and generate high cell density and high product concentration, while considerably reducing culture and processing time.
“We are excited to bring this innovative, high growth technology to Wheaton and to our customers around the world, enabling our customers’ life’s work. These products, combined with the existing Wheaton portfolio, support the advancement of antibody and protein research, development and production,” says Stephen R. Drozdow, president of Wheaton. “We are also proud to have an ongoing partner with Wilson Wolf, for collaboration and further advancement of cell culture products,” he added.
Related Links:
Wheaton Industries
Wilson Wolf Manufacturing
Latest BioResearch News
- Gene Variants Linked to Pollution-Exacerbated Asthma
- Single-Cell Analysis Mapping Links Inflammation Response to Acute Myeloid Leukemia
- Study Reveals New Insights into Rare Blood Cancer Development
- New Findings Clarify Molecular Drivers of Rare Small Intestinal Cancer
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
- Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals
- Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk
- Common White Blood Cells Produce Schizophrenia-Linked Protein
- Nanopore Method Captures RNA Folding at Single-Molecule Resolution
- Tumor Microenvironment Marker Linked to Worse Survival in Solid Tumors
- Hidden Immune Gene Defect May Explain Kaposi Sarcoma Susceptibility
- Genetic Markers May Help Predict Amputation Risk in Peripheral Artery Disease
- Gene Signature Shows Promise for Depression Biomarker Testing
- AI-Driven Tumor Profiling Initiative Targets Precision Therapy Development
Channels
Clinical Chemistry
view channel
FDA-Approved Test Identifies Low Risk of Large Esophageal Varices in Cirrhosis
Chronic liver disease contributes substantially to mortality, and clinicians routinely screen adults with compensated cirrhosis for varices to prevent bleeding. However, endoscopy is invasive and reso... Read more
Blood Protein Signature Diagnoses Pediatric IBD and Distinguishes Subtypes
Confirming pediatric inflammatory bowel disease (IBD) often requires imaging, endoscopy, and histopathology, prolonging time to diagnosis. Reliable, noninvasive blood tests remain an unmet need in routine... Read moreMolecular Diagnostics
view channel
Blood Test Reveals Hidden Pancreatic Cancer After Treatment
Pancreatic cancer often returns even after chemotherapy and surgery, while microscopic disease can remain difficult to detect during surveillance. Standard imaging and broad-panel liquid biopsy tests may... Read more
Model Predicts Increased ALS Clinic Visits with Expanded Genetic Testing
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that rapidly impairs motor function and shortens survival, creating sustained demand for multidisciplinary care.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention
Health systems increasingly rely on economic evidence to guide cancer prevention strategies. For gastric cancer, selecting screening approaches that can integrate with existing programs is a key policy question.... Read more
Machine Learning Reveals Consistent Gut Microbiome Patterns in Colorectal Cancer
Colorectal cancer has been repeatedly linked to alterations in the gut microbiome, yet findings have often varied across small, heterogeneous studies. Reproducibility has been limited by differing sequencing... Read morePathology
view channel
Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
Reliable histologic subtyping guides therapy selection in oncology, yet diagnostic workflows grow more complex as whole-slide imaging and artificial intelligence (AI) expand. A persistent obstacle to clinical... Read more
Study Highlights Biomarker Testing Delays in Lung Cancer Care
Timely biomarker results are critical to match lung cancer patients with targeted therapies or immunotherapies, yet many clinical pathways still delay testing after biopsy. Ordering responsibility, reimbursement... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel








